-
公开(公告)号：US20180163190A1
公开(公告)日：2018-06-14
申请号：US15560076
申请日：2016-03-24
IPC分类号： C12N9/24 , A61P35/00 , C12N15/86 , C07K14/005
CPC分类号： C12N9/2402 , A61K35/761 , A61K38/162 , A61P35/00 , C07K14/005 , C07K2319/00 , C07K2319/035 , C07K2319/33 , C12N15/86 , C12N2710/10043 , C12N2710/10071 , C12N2710/10322 , C12N2710/10332 , C12N2795/00022 , C12N2795/00043 , C12N2795/00071 , C12Y302/01129
摘要： The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.
-
公开(公告)号：US11891598B2
公开(公告)日：2024-02-06
申请号：US16632998
申请日：2018-07-26
IPC分类号： C12N15/03 , A61K39/02 , C12N15/113 , A61K39/00
CPC分类号： C12N15/03 , A61K39/02 , C12N15/113 , A61K2039/55583 , C12N2310/3517
摘要： The present invention relates to a host cell, which comprises under the control of a heterologous promoter a polynucleotide comprising a nucleotide sequence encoding a polypeptide capable of synthesizing a polysaccharide consisting of a dimeric repeating unit as well as to a vaccine composition comprising such host cell. Furthermore, either such host cell or a polypeptide expressed by such host cell is used for the production of a polysaccharide consisting of a dimeric repeating unit which may be used as a glycoconjugate vaccine.
-
公开(公告)号：US20220265799A1
公开(公告)日：2022-08-25
申请号：US17631598
申请日：2020-07-30
IPC分类号： A61K39/00 , G01N33/574
摘要： The invention provides an analytical method for detecting bladder cancer by analysing a urine sample for presence of a glycan tumour antigen, the presence of which has been identified to indicate bladder cancer. The analytical method has the advantage that the tumour antigen can be analysed in a urine sample and has a high accuracy for indicating presence of cancer in the urinary tract, especially bladder cancer, e.g. the method has a low rate of false positive results.
-
4.发明授权公开(公告)号：US10407703B2
公开(公告)日：2019-09-10
申请号：US15303641
申请日：2015-04-17
发明人： Timm Fiebig , Tim Keys , Friedrich Freiberger , Angela Romanow , Andrea Bethe , Monika Berger , Rita Gerardy-Schahn
摘要： The present invention relates to in vitro methods for producing Neisseria meningitidis capsular polysaccharides which have a defined length. The present invention also relates to compositions comprising at least one capsule polymerase, at least one donor carbohydrate and at least one acceptor carbohydrate, wherein the ratio of donor carbohydrate to acceptor carbohydrate is a ratio from 10:1 to 400:1. Moreover, the present invention provides truncated versions of the capsule polymerases of Neisseria meningitidis serogroups A and X. Also provided herein are pharmaceuticals, in particular vaccines, comprising the synthetic capsular polysaccharides of Neisseria meningitidis which have a defined length. Furthermore, the invention provides for methods for the production of said vaccines.
-
公开(公告)号：US20200208134A1
公开(公告)日：2020-07-02
申请号：US16632998
申请日：2018-07-26
IPC分类号： C12N15/03 , C12N15/113 , A61K39/02
摘要： The present invention relates to a host cell, which comprises under the control of a heterologous promoter a polynucleotide comprising a nucleotide sequence encoding a polypeptide capable of synthesizing a polysaccharide consisting of a dimeric repeating unit as well as to a vaccine composition comprising such host cell. Furthermore, either such host cell or a polypeptide expressed by such host cell is used for the production of a polysaccharide consisting of a dimeric repeating unit which may be used as a glycoconjugate vaccine.
-
公开(公告)号：US20210301038A1
公开(公告)日：2021-09-30
申请号：US17263595
申请日：2019-07-31
申请人： Medizinische Hochschule Hannover (MHH) , Deutsches Zentrum für Neurodegenerative Erkrankungen E.V. (DZNE)
发明人： Alexander Dityatev , Hristo Varbanov , Shaobo Jia , Rita Gerardy-Schahn , Evgeni Ponimaskin , Hauke Thiesler , Herbert Hildebrandt , Timm Fiebig
摘要： The present invention relates to a polysialic acid according to the general formula (1) as given as follows and derivatives thereof: (α(2→8)Neu5Ac)n, with n being an integer in the range from 6 to 13, for use in the prevention or treatment of neurological and neuropsychiatric disorders. The present invention also relates to a pharmaceutical composition comprising as an active ingredient said polysialic acid and/or derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to a method of producing said polysialic acid and/or pharmaceutically acceptable salts thereof.
-
公开(公告)号：US10851359B2
公开(公告)日：2020-12-01
申请号：US15560076
申请日：2016-03-24
IPC分类号： C12N9/24 , C07K14/005 , A61K35/761 , A61K38/16 , A61P35/00 , C12N15/86
摘要： The invention provides manipulated adenovirus, i.e. a viral particle based on a manipulated adenovirus, for use as a medicament, especially for use in the treatment of tumours. The viral particle of the invention has the advantage of having a preference or specificity for tumour cells, yielding a preferred infection of tumour cells. The viral particle is based on adenovirus, especially type C, preferably serotype 2 (Ad2), more preferably serotype 5 (Ad5), in which the native entire fiber protein, and its coding sequence, respectively, is deleted and replaced by a fusion protein providing specificity for cell surface bound polysialic acid.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
